Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Cardiac Function in Pediatric Cancer Patients Prior to Anthracycline Chemotherapy
FY 2017-18
Summary
Survivors of childhood cancer face a heightened risk of developing serious heart problems, partially due to their exposure to chemotherapy. Anthracyclines are widely used chemotherapeutic agents, known to cause cardiac toxicity. Current cancer therapy guidelines recommend the use of echocardiography to monitor left ventricular ejection fraction and global longitudinal strain (GLS) in cancer patients before, during and after anthracycline treatment to facilitate the early detection of cardiac toxicity. In a recent study, a group of adult patients with acute leukemia displayed a reduction in GLS even before anthracycline was given, a finding that requires further investigation in children. In general, the significance of pre-chemotherapy cardiac changes and whether they can predict cardiac toxicity after anthracycline exposure in children is poorly understood. My project will address this gap in scientific knowledge and evaluate baseline echocardiograms collected by the Preventing Cardiac Sequelae in Pediatric Cancer Survivors (PCS2) study to first, assess baseline GLS in young cancer patients and compare it to healthy children. We will then identify demographic and disease factors that are linked to abnormal GLS before chemotherapy. We will also explore whether GLS abnormalities at baseline is predictive of worsened heart function during and 1 year after completing anthracycline treatment. We expect lower baseline GLS to accurately predict cardiac dysfunction at 1 year after the last anthracycline dose. Understanding the relationship between cardiac dysfunction prior to starting cancer treatment and subsequent cardiac toxicity may be important for identifying high-risk subgroups of pediatric cancer patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386421
Name
Wang Daniel Y
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cardiac Function in Pediatric Cancer Patients Prior to Anthracycline Chemotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anthracycline; Chemotherapy; Childhood Cancer Survivors; Echocardiography; Global Longitudinal Left Ventricular Strain; Heart Failure; Heart Function; Imaging; Left Ventricular Ejection Fraction; Pediatrics
Abstract
Survivors of childhood cancer face a heightened risk of developing serious heart problems, partially due to their exposure to chemotherapy. Anthracyclines are widely used chemotherapeutic agents, known to cause cardiac toxicity. Current cancer therapy guidelines recommend the use of echocardiography to monitor left ventricular ejection fraction and global longitudinal strain (GLS) in cancer patients before, during and after anthracycline treatment to facilitate the early detection of cardiac toxicity. In a recent study, a group of adult patients with acute leukemia displayed a reduction in GLS even before anthracycline was given, a finding that requires further investigation in children. In general, the significance of pre-chemotherapy cardiac changes and whether they can predict cardiac toxicity after anthracycline exposure in children is poorly understood. My project will address this gap in scientific knowledge and evaluate baseline echocardiograms collected by the Preventing Cardiac Sequelae in Pediatric Cancer Survivors (PCS2) study to first, assess baseline GLS in young cancer patients and compare it to healthy children. We will then identify demographic and disease factors that are linked to abnormal GLS before chemotherapy. We will also explore whether GLS abnormalities at baseline is predictive of worsened heart function during and 1 year after completing anthracycline treatment. We expect lower baseline GLS to accurately predict cardiac dysfunction at 1 year after the last anthracycline dose. Understanding the relationship between cardiac dysfunction prior to starting cancer treatment and subsequent cardiac toxicity may be important for identifying high-risk subgroups of pediatric cancer patients.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Daniel Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~